NOV 16, 2016 8:00 AM PST

The important role of lncRNAs in breast cancer

Sponsored by: Affymetrix, Affymetrix
  • Head of the Cancer Genomics Laboratory; National Institute of Genomic Medicine, Mexico
      Dr. Alfredo Hidalgo-Miranda was born in Mexico City in 1973. He studied Biology and graduated with honors from the National University of Mexico (UNAM) in 1997. In 2005 he received his PhD in Biomedical Sciences from the faculty of medicine from UNAM. Between 1997 and 1999 he was a visiting scientist at the Molecular Oncology Laboratory of the Von Virchow Institute of Pathology at the Von Humboldt University in Berlin, Germany. In 2004 he joined the National Institute of Genomic Medicine (INMEGEN) in Mexico City where he has participated in several projects, including the analysis of genomic diversity of the Mexican population and setting up the genomic analyses core laboratories.

      Since 2013 Dr. Hidalgo-Miranda has lead the Cancer Genomics Laboratory of the INMEGEN where his main research focus is the systematic analysis of somatic alterations leading to human cancer. His group uses high-throughput genomic analysis tools in order to identify changes in the genome and transcriptome of breast tumors, including DNA copy number aberrations, changes in mRNA, microRNA, and lncRNA expression, and how they might be related to tumor biology. The Cancer Genomics group has also been involved in the analysis of whole genome and exome sequencing of breast, uterine cervix, lymphoma, and head and neck tumors, leading to the identification of several genetic abnormalities whose role in human cancer was not previously recognized.
    • Post-Doctoral Associate; Cancer Research Center, University at Albany, State University of New York
        Dr. DeVaux earned her B.S. in Biochemistry at Virginia Tech in 2008 followed by her Ph.D. in Pharmacology from the University of North Carolina in 2013. Her graduate training under Dr. Angelique Whitehurst focused on understanding mechanisms of resistance to anti-mitotic targeted chemotherapeutics in lung cancer. For this work she integrated both medium and high-throughput screening platforms to discover new therapeutic entry points. In 2014 Dr. DeVaux joined the lab of Dr. Jason Herschkowitz at the Cancer Research Center at the University of Albany where she is investigating the role of long non-coding RNAs in promoting breast cancer progression. Her work is supported by the U.S. Department of Defense Breast Cancer Research Program Breakthrough Award.

      DATE:  November 16, 2016
      TIME:  8:00am PT, 11:00am ET 

      Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among women. Hundreds of thousands of women die each year worldwide, and it is estimated that one in eight US women will develop invasive breast cancer in her lifetime.
      The heterogeneity of breast cancer with its unique subtypes and genetic mutation profiles makes developing biomarkers and targeted therapies especially important. In addition, the current standard-of-care for most breast cancers is an aggressive course of therapy to prevent progression and metastasis. This course of treatment, however, is far from optimal and considerable overtreatment is known to occur. Thus, it is critically important to identify the underlying mechanisms that drive breast cancer progression and to find novel biomarkers for early detection, prognosis, prediction of treatment response, and to better inform patient treatment options.
      Long considered to be genomic “junk,” long non-coding RNAs (lncRNAs) have recently gained widespread attention as critical regulators of coding RNA and alternative splicing, and their dysregulation has been associated with tumorigenesis, tumor progression, and metastasis. With only very recent focus, lncRNAs represent a vast source of largely unstudied potential molecular drivers of human cancer, emerging as a new class of promising cancer biomarkers and therapeutic agents.
      During this webinar, our speakers will:
      • Demonstrate how novel transcriptome profiling arrays can reliably identify lncRNAs and lead to the discovery of novel cancer biomarkers
      • Explain the importance of better understanding the role of lncRNAs in breast cancer progression and tumorigenesis
      • Answer your questions live during the broadcast!

      Show Resources
      Show Resources
      • See more
      Connect with us